Your browser is no longer supported. Please, upgrade your browser.
ICON Public Limited Company
Index- P/E31.82 EPS (ttm)6.22 Insider Own4.00% Shs Outstand52.78M Perf Week-2.68%
Market Cap10.49B Forward P/E21.66 EPS next Y9.14 Insider Trans0.00% Shs Float51.97M Perf Month8.64%
Income332.30M PEG2.99 EPS next Q1.97 Inst Own97.00% Short Float5.76% Perf Quarter-7.43%
Sales2.80B P/S3.75 EPS this Y-9.40% Inst Trans2.10% Short Ratio5.09 Perf Half Y-6.58%
Book/sh35.05 P/B5.65 EPS next Y10.04% ROA10.90% Target Price226.85 Perf Year31.25%
Cash/sh15.90 P/C12.45 EPS next 5Y10.65% ROE20.00% 52W Range145.11 - 223.62 Perf YTD1.56%
Dividend- P/FCF20.29 EPS past 5Y9.40% ROI15.60% 52W High-11.44% Beta0.83
Dividend %- Quick Ratio1.90 Sales past 5Y12.20% Gross Margin29.30% 52W Low36.47% ATR5.48
Employees15730 Current Ratio1.90 Sales Q/Q4.80% Oper. Margin14.00% RSI (14)56.95 Volatility2.38% 2.76%
OptionableYes Debt/Eq0.19 EPS Q/Q4.00% Profit Margin11.90% Rel Volume0.86 Prev Close194.07
ShortableYes LT Debt/Eq0.19 EarningsFeb 24 AMC Payout0.00% Avg Volume587.79K Price198.03
Recom2.10 SMA203.44% SMA502.54% SMA2003.21% Volume508,046 Change2.04%
Apr-13-21Resumed BofA Securities Neutral $220
Apr-01-21Upgrade Wells Fargo Equal Weight → Overweight $200 → $235
Mar-08-21Upgrade Robert W. Baird Neutral → Outperform $215
Mar-03-21Initiated Barclays Equal Weight $200
Mar-01-21Upgrade UBS Neutral → Buy $207 → $232
Feb-26-21Upgrade Truist Hold → Buy $280
Jul-24-20Downgrade BofA Securities Buy → Neutral
Apr-20-20Downgrade Robert W. Baird Outperform → Neutral $151
Mar-26-20Upgrade Barclays Equal Weight → Overweight
Mar-02-20Initiated Deutsche Bank Hold
Jan-27-20Downgrade SunTrust Buy → Hold $170 → $182
Jan-08-20Initiated Wells Fargo Equal Weight $180
Jan-07-20Initiated Citigroup Neutral $185
Sep-23-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jul-26-19Upgrade UBS Sell → Neutral
Jan-25-19Upgrade Mizuho Neutral → Buy
Oct-26-18Upgrade Evercore ISI In-line → Outperform
Oct-09-18Initiated UBS Sell
Apr-03-18Downgrade Evercore ISI Outperform → In-line
Feb-15-18Reiterated Mizuho Neutral $109 → $114
Mar-15-21 02:49AM  
Mar-09-21 10:00AM  
Mar-08-21 06:44AM  
Mar-01-21 11:02PM  
Feb-26-21 03:26PM  
Feb-25-21 02:30PM  
Feb-24-21 02:44PM  
Feb-23-21 10:16AM  
Feb-16-21 07:30AM  
Feb-13-21 03:45AM  
Feb-10-21 12:31PM  
Feb-08-21 04:30AM  
Feb-04-21 12:10PM  
Jan-14-21 01:17AM  
Jan-07-21 04:15PM  
Jan-04-21 04:15AM  
Dec-15-20 01:22AM  
Nov-11-20 06:00AM  
Oct-30-20 07:00AM  
Oct-24-20 09:42AM  
Oct-22-20 08:01PM  
Oct-21-20 05:35PM  
Oct-19-20 09:00AM  
Oct-07-20 05:00AM  
Sep-29-20 08:56AM  
Sep-25-20 11:07AM  
Sep-03-20 04:30AM  
Sep-02-20 07:00AM  
Aug-26-20 12:50PM  
Aug-21-20 04:30AM  
Jul-30-20 01:30PM  
Jul-27-20 08:29PM  
Jul-23-20 09:01PM  
Jul-22-20 07:35PM  
Jun-18-20 03:33PM  
Jun-11-20 08:05AM  
May-27-20 06:00AM  
May-26-20 11:40AM  
May-21-20 11:46AM  
May-13-20 06:00AM  
May-05-20 04:30AM  
Apr-22-20 08:55PM  
Apr-18-20 10:28AM  
Apr-10-20 07:51AM  
Apr-09-20 04:30AM  
Apr-03-20 09:05AM  
Apr-02-20 01:04PM  
Mar-23-20 09:56AM  
Mar-19-20 06:57PM  
Mar-15-20 10:01AM  
Mar-03-20 09:00AM  
Feb-21-20 07:09AM  
Feb-19-20 06:55PM  
Feb-12-20 12:31PM  
Jan-27-20 11:54AM  
Jan-22-20 07:46AM  
Jan-21-20 09:11AM  
Jan-17-20 09:15AM  
Jan-14-20 06:00AM  
Jan-13-20 08:30AM  
Jan-01-20 01:43PM  
Dec-08-19 06:22PM  
Dec-05-19 01:00PM  
Dec-04-19 12:14PM  
Nov-27-19 06:00AM  
Nov-14-19 08:30AM  
Oct-30-19 09:42AM  
Oct-29-19 03:03PM  
Oct-23-19 05:55PM  
Oct-17-19 04:28PM  
Oct-16-19 10:32AM  
Oct-15-19 12:11PM  
Oct-04-19 09:39AM  
Sep-13-19 06:00AM  
Sep-11-19 02:18PM  
Sep-03-19 04:15PM  
Aug-23-19 09:40AM  
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.